← Back to Search

Vitamin B3 Analog

Nicotinamide for Skin Cancer Prevention (SPRINTR-Pilot Trial)

Phase 2
Waitlist Available
Led By Joseph Kim, MD PhD
Research Sponsored by Women's College Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial will test if a drug called nicotinamide can help prevent skin cancer in people who have had organ transplants. If it is successful, it will become a larger trial.

Eligible Conditions
  • Non-melanoma Skin Cancer
  • Squamous Cell Carcinoma
  • Basal Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Drug interactions
Feasibility (pertaining to adherence to follow-up assessments)
Feasibility (pertaining to adherence to intervention)
+5 more
Secondary study objectives
Baseline prevalence of cognitive impairment (substudy)
Feasibility of recruiting for neurocognitive substudy
Pooled standard deviation of Animal Naming Task scores (substudy)
+5 more

Side effects data

From 2022 Phase 2 trial • 46 Patients • NCT03061474
25%
Diarrhoea
17%
Urinary tract infection
17%
Fall
8%
Anxiety
8%
Constipation
8%
Vomiting
8%
Laboratory test abnormal
8%
Back pain
4%
Cognitive disorder
4%
Fungal infection
4%
Laceration
4%
Dyspepsia
4%
Pneumonia
4%
Upper respiratory tract infection
4%
Syncoper
4%
Tremor
4%
Agitation
4%
Post lumbar puncture syndrome
4%
Blood testosterone decreased
4%
Weight decreased
4%
Diabetes mellitus
4%
Hyperlipidaemia
4%
Hypokalaemia
4%
Vitamin D deficiency
4%
Arthralgia
4%
Limb injury
4%
Osteoporosis
4%
Glomerular Ffiltration rate decreased
4%
Basal cell carcinoma
4%
Foot deformity
4%
Dizziness
4%
Dysgeusia
4%
Headache
4%
Renal cyst
4%
Neuropathy peripheral
4%
Thrombocytopenia
4%
Eructation
4%
Pleocytosis
4%
Infection
4%
Myalgia
4%
Colorectal cancer
4%
Tooth abscess
4%
Colitis ulcerative
4%
Hiatus hernia
4%
Dehydration
4%
Parkinson's disease
4%
Transaminases increased
4%
Coccydynia
4%
Viral upper respiratory tract infection
4%
Foot fracture
4%
Head Injury
4%
Actinic keratosis
4%
Miliaria
4%
Penile ulceration
4%
Psoriasis
4%
Rash
4%
Urticaria
4%
Cancer surgery
100%
80%
60%
40%
20%
0%
Study treatment Arm
Nicotinamide
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NicotinamideExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide
2021
Completed Phase 3
~2810

Find a Location

Who is running the clinical trial?

NOW FoodsOTHER
5 Previous Clinical Trials
571 Total Patients Enrolled
1 Trials studying Non-melanoma Skin Cancer
396 Patients Enrolled for Non-melanoma Skin Cancer
The Kidney Foundation of CanadaOTHER
15 Previous Clinical Trials
3,175 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,373 Previous Clinical Trials
26,519,122 Total Patients Enrolled
2 Trials studying Non-melanoma Skin Cancer
2,954,144 Patients Enrolled for Non-melanoma Skin Cancer

Media Library

Nicotinamide (Vitamin B3 Analog) Clinical Trial Eligibility Overview. Trial Name: NCT03769285 — Phase 2
Non-melanoma Skin Cancer Research Study Groups: Nicotinamide, Placebo
Non-melanoma Skin Cancer Clinical Trial 2023: Nicotinamide Highlights & Side Effects. Trial Name: NCT03769285 — Phase 2
Nicotinamide (Vitamin B3 Analog) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03769285 — Phase 2
~18 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top